Efficacy of Tocilizumab in COVID-19: Single-Center Experience
Table 1
Characteristics of the patients with COVID-19 infection who received tocilizumab in the mortality group (Group 1) and survival group (Group 2).
Variables
Overall ()
Group 1 ()
Group 2 ()
value
Age (years)
60 (50-70)
70.5 (63-76)
58 (47-68.2)
<0.001
Gender (male)
232 (75.3)
98 (72.6)
134 (77.5)
0.326
Time from SO to HA (days)
7 (5-9)
7 (6-9)
7.0 (6-8)
0.452
Time from SO to TCZ infusion (days)
11 (10-13)
12 (10-13)
11.5 (10-13)
0.755
Duration of oxygen support before TCZ (days)
3 (2-5)
4.0 (2-5)
4.0 (2.7-5)
0.133
Duration of oxygen support after TCZ (days)
6 (4.5-9.5)
17.5 (16-22)
12.5 (8-16)
0.079
Duration of hospital stay after TCZ (days)
8 (7-10)
17.5 (16-22)
15 (14-17)
0.001
Any comorbidity
175 (56.8)
102 (75.6)
73 (42.2)
<0.001
Hypertension
105 (34.1)
71 (52.6)
34 (17.9)
<0.001
Diabetes mellitus
72 (23.4)
46 (34.1)
26 (15)
<0.001
Cardiovascular disease
63 (20.5)
40 (29.7)
23 (13.3)
<0.001
COPD
21 (6.8)
7 (5.2)
14 (8.1)
0.315
Asthma
18 (5.8)
10 (7.4)
8 (4.6)
0.302
Renal insufficient
9 (2.9)
7 (5.2)
2 (1.2)
0.046
Any immunosuppression
4 (1.3)
2 (1.5)
2 (1.2)
0.376
Other
7 (2.2)
6 (4.4)
1 (0.6)
0.191
Oxygen support category before TCZ
<0.001
Low-flow supplemental oxygen
186 (60.4)
62 (45.9)
124 (71.7)
High-flow oxygen or ventilatory support (either noninvasive or invasive)
122 (39.6)
73 (54.1)
49 (28.3)
Oxygen support category after TCZ
<0.001
Low-flow supplemental oxygen
158 (51.5)
57 (42.2)
101 (58.7)
High-flow oxygen or ventilatory support (either noninvasive or invasive)
145 (47.2)
78 (57.8)
67 (39)
None
4 (1.3)
0 (0)
4 (2.3)
<0.001
ICU admission
166 (53.9)
120 (88.9)
46 (26.6)
<0.001
Statistically significant. The categorical data are expressed as (%), and the continuous data are expressed as median (interquartile range (IQR): 25th, 75th percentile). HA: hospital admission; SO: symptom onset; TCZ: tocilizumab; ICU: intensive care unit.
